Table 4.
Kaplan-Meier estimates of overall survival and cancer-specific survival of colorectal cancer patients (n = 1,002).
| Variable | Categories | Cases | Global survival | Cancer-specific survival | ||||
|---|---|---|---|---|---|---|---|---|
| Deaths | 5 years | p-value | Deaths | 5 years | p-value | |||
| All cases | 1,002 | 489 | 58.2 | 422 | 62.3 | |||
| Gender | Male | 520 | 275 | 54.4 | 0.004 | 236 | 58.9 | 0.011 |
| Female | 482 | 214 | 62.3 | 186 | 65.8 | |||
| Age at diagnose | <50 | 290 | 134 | 62.0 | 0.066 | 133 | 62.4 | 0.368 |
| (in years) | ≥50 to <75 | 606 | 299 | 57.0 | 257 | 61.4 | ||
| ≥75 | 106 | 56 | 55.0 | 32 | 67.7 | |||
| Brazilian region of origin | South / Southeast | 822 | 405 | 57.9 | 0.514 | 352 | 61.7 | 0.609 |
| Midwest | 87 | 37 | 65.3 | 32 | 69.8 | |||
| North / Northeast | 93 | 47 | 54.0 | 38 | 59.9 | |||
| Primary tumor site | Right colon | 250 | 111 | 60.0 | 0.289 | 90 | 65.7 | 0.168 |
| Left colon | 466 | 221 | 58.9 | 195 | 62.2 | |||
| Rectum | 285 | 156 | 55.6 | 136 | 59.6 | |||
| Clinical stage (AJCC) | 0/I | 125 | 29 | 86.4 | <0.001 | 15 | 93.9 | <0.001 |
| II | 376 | 126 | 72.5 | 97 | 78.2 | |||
| III | 332 | 175 | 54.4 | 156 | 57.8 | |||
| IV | 167 | 157 | 13.6 | 154 | 13.9 | |||
| Histological type | Adenocarcinoma | 937 | 458 | 58.5 | 0.004 | 395 | 62.6 | 0.009 |
| Mucinous | 58 | 25 | 60.1 | 22 | 62.2 | |||
| Others | 7 | 6 | 14.3 | 5 | 17.1 | |||
| Histological grade | I/II | 924 | 441 | 59.6 | 0.001 | 380 | 63.7 | 0.002 |
| III/Undifferentiated | 63 | 41 | 37.4 | 35 | 41.1 | |||
| Lymphovascular | No | 621 | 227 | 69.7 | <0.001 | 180 | 74.9 | <0.001 |
| invasion | Yes | 300 | 200 | 40.6 | 184 | 42.8 | ||
| Perineural invasion | No | 731 | 301 | 64.9 | <0.001 | 248 | 69.8 | <0.001 |
| Yes | 123 | 89 | 35.4 | 85 | 36.0 | |||
| Presence synchronous | No | 944 | 463 | 58.2 | 0.967 | 403 | 62.1 | 0.487 |
| tumors | Yes | 58 | 26 | 58.6 | 19 | 65.3 | ||
| Presence of recurrence | No | 698 | 245 | 67.8 | <0.001 | 182 | 74.2 | <0.001 |
| Yes | 304 | 244 | 36.5 | 240 | 36.9 | |||
| Treatment period | 2000–2009 | 184 | 142 | 49.5 | <0.001 | 138 | 50.2 | <0.001 |
| 2010–2014 | 818 | 347 | 60.3 | 284 | 65.3 | |||
| Surgery | No | 40 | 38 | 7.5 | <0.001 | 37 | 7.7 | <0.001 |
| Yes | 961 | 450 | 60.4 | 385 | 64.6 | |||
| Neoadjuvant chemotherapy | No | 18 | 14 | 38.9 | 0.002 | 10 | 46.7 | 0.034 |
| Yes | 159 | 80 | 59.1 | 71 | 62.7 | |||
| Adjuvant chemotherapy | No | 543 | 313 | 49.4 | <0.001 | 260 | 54.6 | <0.001 |
| Yes | 442 | 169 | 69.1 | 157 | 71.0 | |||
| Radiotherapy | No | 793 | 376 | 58.6 | <0.001 | 322 | 62.8 | <0.001 |
| Yes, neoadjuvant | 165 | 85 | 58.7 | 73 | 63.0 | |||
| Yes, adjuvant | 21 | 7 | 81.0 | 7 | 81.0 | |||
| Yes, paliative | 21 | 20 | 19.0 | 20 | 19.0 | |||
| AFR | Low | 347 | 171 | 58.0 | 0.403 | 148 | 62.2 | 0.308 |
| Intermediate | 277 | 139 | 56.7 | 119 | 60.8 | |||
| High | 310 | 137 | 60.2 | 114 | 64.9 | |||
| EUR | Low | 316 | 140 | 61.3 | 0.247 | 117 | 66.0 | 0.228 |
| Intermediate | 315 | 160 | 55.0 | 136 | 59.1 | |||
| High | 303 | 147 | 58.8 | 128 | 63.0 | |||
| ASN | Low | 445 | 215 | 57.6 | 0.833 | 184 | 62.1 | 0.819 |
| Intermediate | 205 | 101 | 59.2 | 86 | 63.2 | |||
| High | 284 | 131 | 58.8 | 111 | 63.3 | |||
| AME | Low | 404 | 190 | 58.9 | 0.859 | 167 | 63.0 | 0.949 |
| Intermediate | 231 | 109 | 58.7 | 95 | 61.6 | |||
| High | 299 | 148 | 57.2 | 119 | 63.2 | |||
Significant associations are indicated in bold.